# Reduced Anticoagulation Targets in ECLS (RATE)

Study · id `cardio:ct-nct04536272` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04536272](<https://clinicaltrials.gov/study/NCT04536272>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04536272

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 330 participants.

## Technical summary

Registry record NCT04536272. Randomized; no masking; primary purpose other. Start 2020-10-01 (actual); primary completion 2025-03-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose other
- Phase: Phase 3
- Enrolled: 330 participants (enrolled count; ClinicalTrials.gov record NCT04536272, source copy `cardio:ctgov-nct04536272-2025-05-02`, retrieved 2026-10-26)
- Started: 2020-10-01 (actual) (ClinicalTrials.gov record NCT04536272, source copy `cardio:ctgov-nct04536272-2025-05-02`, retrieved 2026-10-26)
- Primary completion: 2025-03-07 (actual) (ClinicalTrials.gov record NCT04536272, source copy `cardio:ctgov-nct04536272-2025-05-02`, retrieved 2026-10-26)
- Completion: 2025-03-07 (actual) (ClinicalTrials.gov record NCT04536272, source copy `cardio:ctgov-nct04536272-2025-05-02`, retrieved 2026-10-26)
- Countries: Netherlands (ClinicalTrials.gov record NCT04536272, source copy `cardio:ctgov-nct04536272-2025-05-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04536272-2025-05-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Reduced Anticoagulation Targets in ECLS (RATE)
- Acronym: RATE
- Condition: Heart Failure
- Condition: Respiratory Failure
- Condition: Extracorporeal Membrane Oxygenation
- Condition: Bleeding
- Condition: Thrombosis
- Intervention (Drug): Heparin
- Intervention (Drug): LMWH
- Lead sponsor: University Medical Center Groningen
- Lead sponsor class: OTHER
- Collaborator: ZonMw: The Netherlands Organisation for Health Research and Development
- Collaborator class: OTHER
- Collaborator: Erasmus Medical Center
- Collaborator class: OTHER
- Collaborator: Leiden University Medical Center
- Collaborator class: OTHER
- Collaborator: St. Antonius Hospital
- Collaborator class: OTHER
- Collaborator: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Collaborator class: OTHER
- Collaborator: Isala
- Collaborator class: OTHER
- Collaborator: OLVG
- Collaborator class: NETWORK
- Collaborator: Radboud University Medical Center
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record: Heparin (`cardio:heparin`)
- Registry intervention name matches this record: Heparins and low-molecular-weight heparins (`cardio:heparins-and-low-molecular-weight-heparins`)
- Registry intervention is a member of this class by a sourced record link: Anticoagulants (`cardio:anticoagulants`)
- Registry lists this organization as the lead sponsor: University Medical Center Groningen (`cardio:org-university-medical-center-groningen`)
- Registry lists this organization as a collaborator: ZonMw: The Netherlands Organisation for Health Research and Development (`cardio:org-zonmw-the-netherlands-organisation-for-health-research-and-cc2e75`)
- Registry lists this organization as a collaborator: Erasmus Medical Center (`cardio:org-erasmus-medical-center`)
- Registry lists this organization as a collaborator: Leiden University Medical Center (`cardio:org-leiden-university-medical-center`)
- Registry lists this organization as a collaborator: St. Antonius Hospital (`cardio:org-st-antonius-hospital`)
- Registry lists this organization as a collaborator: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (`cardio:org-academisch-medisch-centrum-universiteit-van-amsterdam-amc-662d32`)
- Registry lists this organization as a collaborator: Isala (`cardio:org-isala`)
- Registry lists this organization as a collaborator: Radboud University Medical Center (`cardio:org-radboud-university-medical-center`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial (`cardio:pubmed-42413523`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 876f3874deb0186c7d3fe17183955e039146e56f84599c88f5bbb585ad7abb01
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
